Merck to buy Schering-Plough for $41 billion
Merck & Co. agreed to buy Schering-Plough Corp. for $41 billion in stock and cash.
Drug developer Schering-Plough Corp. spent $520,000 in the first quarter to lobby on patent reform legislation, drug safety and other issues, according to a disclosure report.